Overview

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer With Activating EGFR or HER2 Mutations, Including Exon 20 Insertion Mutations

Status:
Not yet recruiting

Trial end date:
2025-09-01

Target enrollment:

Participant gender:

Summary

This is a Phase 1b, open-label, multi-center, dose-escalation and dose-expansion study designed to evaluate the safety, pharmacokinetics (PK), and preliminary antitumor activity of furmonertinib in patients with advanced or metastatic NSCLC with activating EGFR or HER2 mutations, including Exon 20 insertion mutations. Patients will be enrolled into 2 stages: Stage 1 (Dose Escalation and Backfill Cohorts) and Stage 2 (Dose Expansion).

Phase:

Phase 1

Details

Lead Sponsor:

ArriVent BioPharma, Inc.

Treatments:

Aflutinib